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ABSTRACT
The glycine receptor (GlyR) is the major inhibitory receptor in the brain and spinal cord. A
member of the pentameric ligand gated ion channel superfamily, crystal structures are available
but there are still unresolved areas, specifically the C-terminal tail and TM3-TM4 intracellular
loop. Further refinement can provide deeper understanding of the molecular mechanism and
allow the creation of novel therapeutics to modulate its function. We propose to insert a single
cysteine mutation, I412C, into a Cys null background (C41S/C290A/C345S) to study nonconducting states (resting, desensitized) or with F207G/A288G mutations to study the open state.
Purified, reconstituted GlyR is crosslinked with a Cys-specific photoactivatable
heterobifunctional crosslinker, methanethiosulfonate benzophenone, to produce state dependent
crosslinks. After digestion, mass shifted peptides are analyzed via mass spectrometry to identify
inter- or intracellular crosslinks. Initial results show a different crosslinking pattern between the
three states, mapping dynamic changes in receptor structure upon channel gating and
desensitization. Future work involves more trials refining these crosslinked peptides to single
residue locations.
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CHAPTER 1: INTRODUCTION
1.1 STRUCTURE AND FUNCTION
The glycine receptor (GlyR, Figure 1) is best known for facilitating inhibitory
neurotransmission in the central nervous system (CNS) in response to the binding of glycine 1. It
is an ionotropic receptor in the superfamily of pentameric ligand gated ion channels (pLGIC),
which also includes excitatory nicotinic acetylcholine receptors, serotonin receptors, and
inhibitory type A γ-amino-butyric acid (GABA) receptors2,3. Due to a conserved 15-amino acid
disulfide loop in the ligand-binding extracellular domain, this superfamily is also known as Cysloop proteins2. These proteins, embedded in the lipid membrane, allow the passive movement of
ions down their electrochemical gradient by opening selective pores to form a channel2. GlyRs
are chloride-selective channels and regulate pain sensitivity and transmission, neuromotor
activity, sensory processing, anxiety, and muscle relaxation among others 3,4.
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B

Extracellular
TM1

Transmembrane

TM2

TM4

Intracellular
TM3

Figure 1. Glycine Receptor a) Visualization of GlyR using Protein Data Bank model
3JAD. Each color represents a different subunit. b) Visualization of a single GlyR
subunit (TM3-TM4 intracellular loop not visible in this model).
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These Cys-loop proteins have a large extracellular domain (ECD), four transmembrane
(TM) domains per subunit, and a large intracellular loop linking TM3 and TM4 1,2 (Figure 2). The
primary role of the TM domains is to act as a barrier to separate the lipid bilayer and ion channel
pore1. TM1, TM3, and TM4 surround TM2, which lines the pore, and isolate TM2 from the
hydrophobic environment 1. GlyR can exist as a homomeric receptor, consisting of five αsubunits, or as a heteropentameric receptor, consisting of a mixture of α- and β-subunits, with
ratios of either 2α3β or 3α2β 3,4. The dominant stoichiometry in adults is two α-subunits and
three β-subunits5. Four α-subunits and one β-subunit have been characterized and found to be
expressed in the CNS during its development and maturation4. The α1 subunit is widely
A

B

C

D

Figure 2. Glycine Receptor Topology a) A schematic representation of the α1
subunit of GlyR. Adapted from reference 2. b) Representation of the α1 subunit of
GlyR. ECD colored gray, TM colored yellow with TM2, part of the channel pore,
colored magenta, intracellular loop colored light blue, and C-terminal region colored
cyan. Adapted from reference 4. c) Representation of the GlyR pentamer which shows
TM2 surrounding the channel’s pore. Adapted from reference 4. d) Representation of
two GlyR subunits illustrating the glycine-binding site (GBS). Loops (A-C) and βstrands (D-F) comprising the GBS are labeled as well. Amino acids from the principal
subunit are colored red and amino acids from complementary subunit are colored
orange. Adapted from reference 4.
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expressed in the adult CNS, and has been the focus of much research4. Glycine binds at the
interface of two subunits, either α and α or α and β4. The binding of glycine activates GlyR,
opening the channel pore to allow for the movement of anions down their electrochemical
gradient; this flux of chloride ions causes hyperpolarization of the membrane, and the following
inhibition of neuronal activity6.
1.2 DYSREGULATION AND TREATMENT
GlyR is involved in the hereditary neurological disorder, hyperekplexia, an autosomal
dominant disorder characterized by an exaggerated startle response to tactile or acoustic stimuli
and an increased tightness in muscle tone that often results in spasticity and rigidity7. Hypertonia
begins at birth, and even normal handling of infants can cause massive skeletal contractions 7.
The severity of cases ranges, with severe neonatal cases potentially leading to cardiac arrest and
death during an episode8. The hypertonia wanes as those affected become older, but the
exaggerated startle response persists along with transient muscle contractions, which can cause
them to fall unchecked, thus resulting in injuries and possibly chronic pain7. With hyperekplexia
also comes an increased likelihood of intellectual disability, delayed speech acquisition, and
apnea attacks9. The exaggerated startle response is characterized by forceful eye closure, flexion
of joints including the elbows, hips, knees, trunk, and neck, and the rising of bent arms over the
head9. These startle responses are distinguished from epileptic seizures because consciousness is
fully retained9. There are dozens of point mutations linked to hyperekplexia, but the most
frequently occurring is the point mutation at amino acid 271, arginine, in the α1-subunit of GlyR,
changing it to glutamine or leucine9. However, current therapeutic treatments do not target
GlyR10. The most common treatment for hyperekplexia is clonazepam, which targets γ-aminobutyric acid receptor through increasing GABA-gated chloride channel function8. It is presumed
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that this enhancement compensates for the decrease in GlyR-gated chloride channel function8.
Research on the effectiveness of clonazepam varies, with some finding it successful and others
finding it less effective in treating this rare startle response 8.
Chronic pain is a common problem in the United States, with heavy social,
psychological, physical, and economic impacts. Up to 50% of chronic pain sufferers have found
little to no relief with existing available treatments, which have dose-limiting side-effects and
limited analgesic efficacy5,11. Chronic pain has been found to severely reduce the psychological,
physical, and social wellbeing of those suffering from it 12. As of 2012, chronic pain costs the
United States $600 billion per year11. GlyR is a major potential target for drugs in treating
chronic inflammatory pain, particularly cannabinoids13. GlyRs that contain an α3 subunit
concentrate in regions of the dorsal horn of the spinal cord, which is where nociceptive afferents
terminate14. Additionally, GlyRs containing α3 subunits are inhibited by inflammatory
mediators, and the deletion of an α3 gene leads to insensitivity to chronic inflammatory pain14.
These factors implicate promising results for analgesic therapies that increase flux through
GlyRs containing α3 subunits. Cannabidiol (CBD), a non-psychoactive component of marijuana,
and altered derivatives of CBD were shown to suppress inflammatory and neuropathic pain with
no significant analgesic tolerance or psychoactive side effects 15. Thus, cannabinoids are a
promising potential therapeutic agent to treat chronic inflammatory pain and other disorders
involving dysfunction of GlyR. However, due to the social stigma surrounding marijuana and
CBD, use of this potential novel therapeutic is highly contentious, leading to continued demand
for new therapeutics to treat GlyR dysregulation and chronic inflammatory pain. Having a
detailed structure and knowledge of the allostery of GlyR is vital in producing successful novel
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therapeutics to modulate its function; consequently, it is important that research be done to
clarify these.
1.3 ALLOSTERIC STATES
GlyR has three major allosteric states: the desensitized state, resting state, and active state
(Figure 3), in addition to several intermediate states within the allosteric transitions 16. The
resting state, also known as the apo state, of GlyR has no ligand bound to it and is
nonconducting16. As glycine binds to GlyR, GlyR transitions to an open conformation, or the
active state, for several milliseconds, which opens the channel pore at the central axis, allowing
the passive diffusion of chloride ions and subsequent membrane hyperpolarization4. Following
this activation, GlyR enters the longer desensitized, or closed, state for several seconds while the
neurotransmitter, glycine, is still bound17. During desensitization, the channel pore is constricted
by TM2 and TM3 interactions, preventing the passive diffusion of chloride ions17. Ivermectin

A

B

C

Figure 3. a. Schematic illustration of GlyR in the closed state with strychnine bound
and no movement of chloride ions, b. in the resting state with no ligand bound and no
movement of chloride ions, and c. in the open state with IVM bound and movement of
chloride ions. Figure is adapted from reference 19.
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(IVM) is an agonist of the GlyR chloride channel, acting as a positive allosteric modulator that
binds between subunits not just for GlyR, but all members of the pLGIC family18. At low
concentrations, IVM potentiates GlyR, keeping it in an open conformation, or its active state 18.
At high concentrations, IVM irreversibly activates GlyR18. Strychnine is an antagonist of GlyR,
binding competitively against agonists, including glycine19. Upon strychnine binding, the
intracellular loop linking TM2-TM3 displaces inwardly, shutting the channel pore19. IVM-bound
GlyR displays dramatically reduced sensitivity to strychnine inhibition compared to glycinebound GlyR18.
1.4 CLASSIC TECHNIQUES TO RESOLVE PROTEIN STRUCTURE
X-ray crystallography and cryogenic electron microscopy (cryo-EM) are both highresolution techniques that result in a crystal structure of molecules. Current crystal structures of
GlyR have been elucidated while it is bound to strychnine and IVM19,20 (Figure 4). X-ray
crystallography was a big development in resolving protein structures, but it has some

A

B

Figure 4. a. Crystal structure of GlyRα3 bound to strychnine, and b. bound to
ivermectin. Figure is adapted from references 20 and 21.

7
limitations, such as requiring a significant amount of sample, proteins having significantly
different conformations in crystal form than in solution, and not being able to provide a
comprehensive, correct structure of transmembrane proteins21. Additionally, crystal structures
are an amalgamation of images throughout time that appear to be a snapshot of the protein at one
instant21. Flexible, or mobile, protein regions have to be shortened for diffraction analysis due to
the incapacity of some crystals to diffract to atomic resolution21. This incapacity to achieve
atomic resolution of mobile protein regions results in significant errors in the structures
produced21. GlyR is one of these flexible transmembrane proteins with various allosteric states,
so limitations in using the crystal structure as the GlyR model include the lack of information in
flexible regions and of the changes that occur as it transitions between allosteric states.
Cryo-EM rapidly lowers the temperature of protein samples to a cryogenic level to
prevent the crystallization of water in the solution; vitrification can be used, which involves
liquid nitrogen temperatures22. This sample is then subjected to an electron beam, and the
resulting diffraction pattern is analyzed by a transmission electron micrscope 22. Cryo-EM has
several advantages over X-ray crystallography, such as determining the structures in a
transmembrane molecule’s local, physiological environment and of the transient structural states,
by freezing proteins in their transitional state22. Yet, similar to X-ray crystallography, cryo-EM
does not provide structural information about the changes occurring as proteins transition
between states22. Even with both of these techniques, GlyR models have poorly resolved, or even
missing, areas, including the C-terminal tail, TM3-TM4 intracellular loop, and the resting
structure. Further refinement of the GlyR model should be done by improving these methods or
combining these methods with other techniques.
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1.5 CROSSLINKING MASS SPECTROMETRY TO RESOLVE PROTEIN STRUCTURE
Crosslinking mass spectrometry (CXMS) has improved opportunities to map structural
details of functional complexes in solution23. Crosslinking alters non-covalent interactions
between proteins and makes them covalent bonds, so these fused molecules withstand
denaturation and can be analyzed with methods that typically separate protein complexes 23. Mass
spectrometry (MS) identifies which residues are involved in these crosslinks, thus providing
constraints for any modelling attempts, as residues have to be within a certain distance to be
crosslinked, which is why this is referred to as a molecular ruler23,24. A typical CXMS study
involves four steps: crosslinking, digestion, MS and MS/MS, and data analysis (Figure 5). First,
a crosslinker is added to a purified protein sample and activated, such as with UV light, to bind
with certain residues; the crosslinker used depends on the study and proteins, but it will be of
known length and have a reactive group on either end (crosslinkers with three reactive groups

Figure 5. Process of a typical CXMS study. Figure is adapted from reference 24.
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exist but are rarely used)23. SDS-PAGE is used to separate the monomeric and oligomeric
fragments, and these fragments are digested into peptides by a protease, usually trypsin23,24. MS
is then used to identify crosslinked peptides and MS/MS is used to further refine this and identify
the specific crosslinked residues23. Finally, this data is taken to protein databases to analyze it 23.
CXMS is useful for protein structure analysis for several reasons: MS has high
sensitivity, crosslinking reactions can be done at physiological pH so proteins can be studied in
their native conformation, and it can be performed on transmembrane proteins, highly flexible
and dynamic protein complexes, and large protein assemblies24. While CXMS on its own may
not provide enough information to form a complete structure model, it can be used with other
techniques, such as X-ray crystallography and cryo-EM, to reveal protein structure of these
dynamic proteins24. CXMS provides useful structural information in two general research areas:
conformational changes in proteins and protein-protein interactions24.
1.6 RESEARCH DESIGN
This project aims to provide more structural information of GlyR, especially its allosteric
changes and one of its currently unrefined areas, the TM3-TM4 intracellular loop. CXMS will be
used to provide this structural information. Each allosteric state will be studied to provide
information on GlyR dynamics, which have not been successfully refined in current crystal
structures with the classic protein resolving techniques discussed above. This project focuses on
one specific location, I412C, where an isoleucine is substituted with a cysteine, in a cys-null
background. Crosslinking will be done in this location with a photoactivatable
herterobifunctional methanethiosulfonate (MTS)-benzophenone that is approximately 25 Å long
(Figure 6). This crosslinker will first form a disulfide bone with the inserted cysteine residue at
position 412. Once activated with UV light, it will non-selectively bind to amino acids within 25
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Å by forming a radical, which initiates a carbon-carbon bond formation with an α-carbon of
nearby amino acids. Performing this with each allosteric state, in addition to combining this
project with information from other specific locations on GlyR, will provide information about
GlyR’s molecular mechanism, leading to a more refined and dynamic GlyR model. Having a
refined and dynamic GlyR model will aid in the process of creating novel therapeutics to target
GlyR and modulate its function.

Figure 6. Crosslinker MTS-benzophenone with reactive groups boxed in red. Molecular
weight is 390.47 g/mol. The MTS group forms a disulfide bond with I412C upon its addition
to purified GlyR. The oxygen of the benzophenone group forms a radical upon UV activation
and non-selectively binds to nearby amino acids.
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CHAPTER 2: MATERIALS AND METHODS
2.1 MUTAGENESIS OF GlyR
A pFastBac plasmid, which contains ampicillin resistance gene for bacterial selection,
encodes for either Cys null GlyR in order to study the desensitized and resting states or Cys null
GlyR with a double mutation (F207G/A288G) in order to study the open state. The additional
double mutation increases GlyR’s sensitivity to IVM. The Cys null background occurs when the
three active cysteines are mutated into serine or alanine (C41S/C290A/C345S) to guarantee that
the crosslinker, MTS-benzophenone, will only bind to the one mutated active cysteine (I412C).
2.1.1 Mutagenic Primer Design (performed by other members of Cascio lab)
Mutagenic primers introduce single site-specific cysteine mutations. Both forward and
reverse primers containing the desired mutation for polymerase chain reaction (PCR) cycling
were designed in the Cascio lab (Veeramachaneni) according to the QuikChange Site-Directed
Mutagenesis manual26. The primers annealed to the same sequence on opposite sides of the
plasmid26.
2.1.2 Mutant Strand Synthesis Reaction (PCR Cycling) and Digestion of Parental DNA
(performed by other members of Cascio lab)
Using the QuikChange Site-Directed Mutagenesis kit, a cysteine was placed in position
412 to replace an isoleucine (I412C). Reaction mixtures (Table 1) were placed in thin-walled
PCR tubes and ran through temperatures to allow denaturation, annealing, and elongation, which
were optimized in the Cascio lab26. A Dpn 1 restriction enzyme (2 µL) from the QuikChange kit
was then added to the DNA to digest the non-mutated, or methylated, parental DNA, leaving
behind the DNA of the desired mutation26.
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Table 1. PCR reaction mixtures
Reaction

Reaction component

Amount added (µL)

Positive control

10 X reaction buffer

5

pWhitescript 4.5 kb control primer

5

Oligo control primers 1 and 2

1.25 of each

dNTP mix

1

dI water

35.5

QuikChange Lightning Enzyme

1

10 X reaction buffer

5

pWhitescript 4.5 kb control primer

5

Oligo control primers 1 and 2

1.25 of each

dNTP mix

1

dI water

36.5

10 X reaction buffer

5

Cys null GlyR in pFastBac

2

Forward primer

1.25

Reverse primer

1.25

dNTP mix

1

QuikSolution reagent

1.5

dI water

38

QuikChange Lightning enzyme

1

IVM- Sensitive Cys

10 X reaction buffer

5

null GlyR

Cys null + (F207G/A288G) GlyR in pFastBac

2

Forward primer

1.25

Revere primer

1.25

dNTP mix

1

QuikSolution reagent

1.5

dI water

38

QuikChange Lightning Enzyme

1

Negative control

Cys null GlyR
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Table 2. PCR cycling parameters
Cycle 1

95ºC for 30 seconds

Cycle 2

95ºC for 30 seconds

Cycle 3

55ºC for 1 minute

Cycle 4

68ºC for 7 minutes

Cycle 5

Repeat cycles 1-4 for a total of 16 times

Final step

Hold at 4ºC

2.1.3 Transformation of XL10-Gold Ultracompetent Cells (performed by other members of
Cascio lab)
XL10 Gold cells from Agilent (45 µL) were added to round-bottom Falcon tubes,
followed by 2 µL of β-mercaptoethanol and Dpn 1-treated DNA from the control and samples26.
The Falcon tubes were incubated on ice for 30 minutes and then heat pulsed for exactly 30
seconds in a 42ºC water bath, and then they were immediately incubated on ice for an additional
two minutes26. A liquid media, super optimal broth with catabolite repression, was added to each
tube; following one hour of incubation at 37ºC, 10 µL of broth was plated onto Luria broth (LB)ampicillin agar plates26. The plates were incubated at 37ºC overnight 26. The next day, single
colonies were picked and added to Flacon tubes with 2 mL of LB media and 0.05 mg/mL
ampicillin; these tubes were shake-incubated at 37ºC overnight 26. The DNA was then purified
using UltraClean Standard Mini Plasmid Prep Kit and procedure (MoBio) 26. The concentration
of DNA in the samples was determined using a Nanodrop-1000 spectrophotometer and a 0.8%
agarose DNA gel was run, stained, and imaged to verify the mutation success 26.
2.2 OVEREXPRESSION OF MUTANT GlyR
The Invitrogen FastBac Bacuovirus System (Figure 7) was used to transpose the
pFastBac donor plasmid containing the mutated GlyR into a baculovirus shuttle vector (bacmid)
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containing transposon elements, antibiotic resistance genes, and a lacZα gene26. Blue/white
selection was used to identify colonies containing the GlyR gene and extract the bacmid to
transfect Spodotera frugiperda (Sf9) insect cells26. Viral stocks were harvested, amplified, and
titered from these cells to infect new Sf9 cells to achieve overexpression of GlyR26.

Figure 7. Guide to FastBac Baculovirus Expression System. This diagram shows the
process of overexpression; steps include extraction of bacmid DNA, transfection into
Sf9 insect cells, viral titer determination, and infection of Sf9 insect cells. Figure is
adapted from reference 25.
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2.2.1 Transposition of DH10Bac Cells
100 µL aliquots of DH10Bac competent cells from Invitrogen were pipetted into Falcon
tubes, followed by 5 µL of the purified, mutated plasmid26. In a control tube, 100 µL of cells
were added to 2 µL of PUC-1926. After 30 minutes of being incubated on ice, the cells were heat
shocked in an exactly 42ºC water bath for exactly 45 seconds26. Following this, the cells were
incubated on ice for 2 minutes before 900 µL of SOC media was added, after which they were
shake incubated for 4 hours at 37ºC26. Three serial dilutions were prepared by adding 100 µL of
the more concentrated cells to the next tube with 900 µL of SOC media26. 100 µL of each
dilution was plated on LB-kanamycin-gentamycin-tetracycline plates, which were incubated for
40-48 hours at 37ºC26. The plates contained 0.04 mg/mL isopropyl-β-thiogalactopyranoside and
0.3 mg/mL halogenated indolyl-β-galactoside (X-Gal) to allow the development of blue and
white colors26.
2.2.2 Blue-White Screening
White colored colonies represented GlyR that had been successfully transposed into
recombinant bacmid, as the lacZ operon is where transposition occurs in the bacmid DNA; the
the GlyR gene disrupts this operon, so the enzyme that cleaves X-gal is not made. In blue
colonies, transposition was not successful and the lacZ operon was function, making an enzyme
that cleaves X-gal, resulting in a blue color. Solitary white colonies were taken from the plate
and placed in a Falcon tube with 2 mL LB media, 1.66 µL tetracycline (12 mg/mL), 1.4 µL
gentamycin (10 mg/mL), and 10 µL kanamycin (10 mg/mL)26. The tubes were shake-incubated
at 225-250 rpm for 16 hours at 37ºC26.
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2.2.3 Extraction of Recombinant Bacmid DNA
After incubation, 1 mL of culture was transferred to a 2 mL collection tube and
centrifuged for 2 minutes at 13,000 x g, and the supernatant was discarded26. This was repeated
in the same tube until all culture was centrifuged. 300 µL of solution 1, consisting of 10 mM
ethylenediaminetetraacetic acid (EDTA), 15 mM 2-amino-2-(hydroxymethyl)propane-1,3diolhydrochloride (Tris-HCl) at pH 8, and 100 µg/mL RNAse A, along with 300 µL of solution
2, consisting of 0.2M NaOH and 1% SDS were added to the tubes26. The samples were mixed
gently by pipetting up and down, and were incubated at room temperature for 5 minutes, until the
solution was translucent 26. 300µL of 3M potassium acetate was added dropwise and the solution
was gently mixed and incubated on ice for 5-10 minutes as a white precipitate formed26. The
samples were centrifuged for 14 minutes at 13,000 x g and 4ºC, and the resulting supernatant
was transferred to collection tubes containing 800 µL ice-cold isopropanol26. The collection
tubes were mixed by gentle inversion and incubated at -20ºC overnight or longer26. Samples
were centrifuged at 13,000 x g for 18 minutes at 4ºC and supernatant was discarded26. 500 µL of
70% ethanol was added and the sample was inverted several times to wash the pellet, and
centrifuged at 13,000 x g for 7 minutes at room temperature26. Again, the supernatant was
removed, and the remaining pellet was air-dried at room temperature for 5-10 minutes to allow
the ethanol to evaporate26. Once the ethanol was evaporated, the DNA was dissolved by adding
40 µL TE buffer and gently tapping the tube26. Concentrations and purity ratios were determined
with NanoDrop, and the sample was stored at 4ºC (or -20ºC for long term storage)26.
2.2.4 Transfection of Sf9 Insect Cells with Recombinant Bacmid DNA
2 mL of Sf9 cells were added to a well plate, which was incubated at 27ºC, allowing cells
to adhere to the plate walls26. Two 1.5 mL centrifuge tubes were prepared, one with 100 µL
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Grace’s Insect Media and 1 µg of bacmid DNA, and one with 100 µL Grace’s Insect Media and
6 µL cellfectin from Invitrogen26. The two solutions were then mixed together and incubated for
15 minutes at room temperature26. Media from the well plates was carefully removed to not
disturb the cells, and 2 mL of Grace’s Insect Media containing 10% fetal bovine serum (FBS)
and 100 µg/mL penicillin-streptomycin was added26. 800 µL of Grace’s Insect Media was added
to the mixture of Grace’s Insect Media, cellfectin, and bacmid DNA, and 160 µL of this resulting
mixture was transferred to the well plate containing Sf9 cells26. The well plates were incubated at
27ºC overnight, then the media was removed from the plates again26. 2 mL of Grace’s Insect
Media containing FBS and penicillin-streptomycin was added, and this was incubated for 72
hours26.
2.2.5 Viral Titer
A 96 well plate was acquired and 50 µL of poly-D-lysine (5 mg/50 mL) was added to
each well. The well plate was incubated for 30 minutes at 28ºC. The poly-D-lysine was removed
and 1 drop of sterile PBS (1X) was placed in each well, about 10 µL total, and gently shook. The
PBS was removed and the plate dried in the hood for one hour. 100 µL of cells were added to
each well, which was then covered with parafilm and incubated at 27ºC for 45 minutes. Mixtures
(Table 3) were placed in 1.5 mL centrifuge tubes. 100 µL of each mixture was placed into
corresponding wells (tube 1 into wells in column 1, etc.), and the well plate was incubated for 1
hour at room temperature. Following incubation, the media was removed and 200 µL of fresh
complete media was added into each well. The well plate was sealed and incubated overnight.
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Table 3. Viral titer mixtures
Reaction

Reaction component

Amount added (µL)

Tube 1

Complete media

990

Tube 2

Complete media

990

Control virus

10

Complete media

990

Virus

10

Complete media

990

Virus

10

Complete media

990

Virus from tube 3

10

Complete media

990

Virus from tube 4

10

Complete media

900

Virus from tube 5

100

Complete media

900

Virus from tube 6

100

Complete media

900

Virus from tube 7

100

Complete media

900

Virus from tube 8

100

Complete media

900

Virus from tube 9

100

Complete media

900

Virus from tube 10

100

Tube 3

Tube 4

Tube 5

Tube 6

Tube 7

Tube 8

Tube 9

Tube 10

Tube 11

Tube 12

Liquid media was removed and 50 µL of 4% paraformaldehyde was added in all wells,
and incubated for 20 minutes at room temperature. A blocking buffer consisting of 3.6 µL of
10% Tween, 360 µL of 5% normal goat serum, and 6,836.4 µL of 1X PBS was prepared and 50
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µL was added to each well after incubation and removal of media. Cells were incubated for an
additional hour at room temperature. In a 1.5 mL centrifuge tube, 1.5 mL blocking buffer and 1.5
µL 1º antibody was added. After incubation, the blocking buffer was removed and 50 µL of the
blocking buffer/antibody solution was added to each well. After 1 hour of incubation at room
temperature, cells were washed three times with a wash buffer consisting of 1X PBS, 1% normal
goat serum, and 0.05% Tween. 2.5 mL of wash buffer and 2.5 µL of 2º antibody were added to a
15 mL conical tube. After the last wash was removed, 100 µL of the wash buffer/2º antibody
solution was added to each well and the plate was incubated for 1 hour at room temperature. The
cells were again washed three times with 100 µL of wash buffer. Meanwhile, a color solution
was prepared in a 1.5 mL centrifuge tube: 6 µL of X-gal in dimethylformamide (DMF) (0.05 g
X-gal in 1 mL DMF), poly(nonylbithiazole) (PNBT) in DMF (0.083 g PNBT in 1 mL DMF), 15
µL of 500 µM magnesium chloride, and 1.473 mL of 1X PBS. Upon removal of the last wash,
100 µL of coloring solution was added to each well and the cells were incubated at 37ºC until
color production occurred, checking every 10 minutes. The number of cells in the wells was then
counted and, now knowing the plaque forming units per mL (pfu/mL), the volume of virus
needed to infect Sf9 cells was calculated using Equation 1, using a multiplicity of infection
(MOI) of 5.
Equation 1: 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑉𝑖𝑟𝑢𝑠 (𝑚𝐿) =

𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑀𝑂𝐼
𝑝𝑓𝑢
𝑜𝑓
𝑚𝐿

𝑣𝑖𝑟𝑢𝑠

×

𝑛𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
1

Equation 1 illustrates the volume of amplified virus added to approximately 750 mL of
Sf9 cells. The cells were incubated for 3 days after infection and harvested by centrifugation.
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2.3 PREPARATION AND RECONSTITUTION OF GlyR
GlyR needs to be prepared, or purified from all other proteins in order to study the mutant
GlyR. A 2-aminostrychnine column was adapted27 as GlyR and strychnine bind with high
affinity. Following purification, the GlyR was reconstituted back into lipid vesicles.
2.3.1 Solubilization of Membrane Proteins
Unless noted otherwise, all steps were performed at 4ºC or on ice. After 3 days of
incubation, the cells were centrifuged at 2,000 x g for 10 minutes and the supernatant was
disposed. In a 15 mL conical tube, the cell pellets were then washed with 10 mL of an isotonic
phosphate buffered saline solution (PBS, pH 7.4) and resuspended in up to 10 mL of a hypotonic
solution consisting of 5 mM Tris pH 8, 5mM EDTA, 5 mM EGTA, and 10 mM dithiolthreitol
(DTT) to cause cells to swell. The following antiproteolytics were added as well to prevent
protein degradation: 2 µL of aprotinin (1.6 microunits/mL), 20 µL of 100 mM benzethonium
chloride, 40 µL of 1 mM benzamide, and 20 µL of 100 mM phenylmethylsulfonylflouride
(PMSF). After 1 hour of ice incubation, the antiproteolytics were added again, and a probe tip
sonicator microtip set to max was used to sonicate the solution in 15 second bursts 6 times to
lyse the cells, placing the tube in an ice bath between bursts to allow for heat dissipation. A
Beckman type 70.1 ultracentrifuge was used to centrifuge the solution at 65,000 rpm for 30
minutes with low brakes. The resulting pellet, which contained membrane proteins, was
resuspended in approximately 10 mL of a resuspension buffer containing 10 mL of the hypotonic
solution and 640 µL of 300 µM NaCl. Peripheral membrane proteins were removed from the cell
membrane through centrifugation at 100,000 x g for 5 minutes. Then, the cells were sonicated
and centrifuged using the same previous protocol. The subsequent pellet was resuspended in 10
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mL of 1% digitonin and 1% deoxycholate buffer solution with DTT to solubilize the membrane
proteins. This solution was shake-incubated at 4ºC overnight.
2.3.2 Affinity Chromatography with 2-aminostrychnine
After overnight incubation, the solubilized proteins were centrifuged at 65,000 rpm for 30
minutes and the supernatant was decanted to a fresh tube. This supernatant was added to 2aminostrychnine agarose in 15 mL conical tubes. Again, the solution was shake-incubated at 4ºC
overnight. This solution was centrifuged for 5 minutes at 2,000 rpm and the supernatant was
stored. The resin left behind was liberally washed with cholate wash buffer 3 times, containing
2.5 mL of 1.5 mg/mL lipids, 5 mL of 1% cholate, 450 µL of 25 mM K2HPO4, 150 µL of 25 mM
KH2PO4, 1.87 g of 1 M KCl, 250 µL of 5 mM EDTA, and 250 µL of 5 mM EGTA, and diluting
it with 25 mL dH2O. Depending on the state being studied, 1.5 mL of 1.5 mM glycine or
strychnine was added to 15 mL of cholate wash buffer to create an elution buffer. 4 mL of this
elution buffer was added to 4 mL of resin and the resulting solution was shake-incubated for 2
days at 4ºC. This was spun down for 5 minutes at 3,000 rpm and the supernatant was collected. 3
more mL of elution buffer was added and this was repeated – centrifugation and collection of
supernatant containing pure GlyR.
2.3.3 Reconstitution of Purified GlyR
Dialysis was performed to reconstitute purified GlyR into lipid vesicles. Purified GlyR
was placed in a solution of 0.5 mL of 1.5 mg/mL mixed lipids and 295 µL of cholesterol,
sonicated for 10 seconds 2 times, and placed in a dialysis cassette from Thermo (3,500 MWCO).
The dialysis cassette was then submerged for two hours in a 2 liter KPi solution (Table 4)
containing 74.55 grams of 0.5 M KCl and 1 gram of biobeads. After 2 hours, it was transferred to
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a new 2 liter KPi solution containing 37.275 grams of 0.25 KCl and 1 gram of biobeads for
another 2 hours. After this, it was transferred to a 3 liter KPi solution containing 3 grams of
biobeads and left to sit overnight. The next day, the dialysis cassette was transferred to a 5 liter
KPi solution. After 24 hours had passed, the solution was removed from the dialysis cassette and
added to 0.5 mL of mixed lipids and 295 µL of cholesterol and sonicated 2 times for 10 seconds.
The sonicated solution was centrifuged for 30 minutes at 65,000 rpm and the supernatant and
pellet were collected. 0.7 mL of mixed lipids was added to the collected supernatant, and the
resulting solution was sonicated twice for 10 seconds. This was placed in the dialysis cassette
which was placed in a 3 liter KPi solution for 24 hours. This was replaced with another 3 liter
KPi solution for another 24 hours. As before, lipids and cholesterol were added and it was
centrifuged, but only the pellet was reserved.
Table 4. KPi Solutions
Volume of 25 mM KPi

KH2PO4 needed (grams)

K2HPO4 needed (grams)

1

3.4

4.35

2

6.8

8.7

3

10.2

13.05

5

17

21.75

solution (liters)

2.4 VERIFICATION AND QUANTIFICATION OF GlyR
A Western blot assay was performed to verify that GlyR was purified and to confirm if
any protein was lost during steps of the purification process. A Modified Lowry assay was
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performed to find the concentration of GlyR, allowing the appropriate amount of crosslinker to
add to be determined.
2.4.1 Western Blot
An SDS-polyacrylamide gel electrophoresis (PAGE) acrylamide gel was prepared with
10 wells (15% resolving gel pH 8.8, 5% stacking gel pH 6.8). 14 µL of pure GlyR protein
sample was added to 4 µL of 5x running dye and 2 µL of 10 mM DTT and added to the wells.
Aliquots of cell fractions from the GlyR preparation were also added to the wells. Once
electrophoresis was completed, the gel was placed onto a nitrocellulose membrane which was
immersed in Odyssey blocking buffer from LI-COR. 2 µL of primary antibody, monoclonal antirabbit against GlyR (1:5000, GeneTex, Odyssey), in 10 mL of 1X PBS was added and this was
incubated for 1 hour. Post-incubation, the membrane was washed 4 times with PBS and 0.1%
Tween 20. Before incubating the membrane for 1 more hour, 2 µL of a fluorescent secondary
antibody, goat anti-rabbit (1:10,000, LICOR, Odyssey) was added. The nitrocellulose membrane
was then washed and was imaged with an Odyssey infrared imager. Bands in the purified GlyR
sample well at 49 kDa confirmed the expression of mutated GlyR.
2.4.2 Modified Lowry Assay
The Modified Lowry Assay is used to determine the total level of protein in solution. A
bovine serum albumin (BSA) standard curve was constructed with concentrations ranging from 1
– 20 µg/mL, diluted to 1 mL with dI water. 25 µL and 50 µL aliquots of pure GlyR with and
without IVM were also diluted to 1 mL with dI water. All calibration points were run in
duplicates. In order to precipitate protein, 150 µL of 1% deoxycholate was added to each tube,
the tubes were vortexed, and then incubated at 20ºC for 10 minutes. 100 µL of 72%
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trichloroacetic acid was added to each tube, the tubes were vortexed again, and centrifuged for
10 minutes at 3,000 x g (7,000 rpm). The supernatant was carefully aspirated and discarded
before 200 µL of dI water was added to each tube. In the dark, 6 mL of 1x Folin-Ciocalteau
reagent was prepared by dilution with dI water. 1 mL of modified Lowry reagent (Thermo) was
added to each tube at 15 second intervals, the tubes were vortexed, and incubated at 20ºC for
exactly 10 minutes. In the dark, 100 µL of the prepared 1x Folin-Ciocalteau reagent was added
to each tube in 15 second intervals, in the same order the modified Lowry reagent was added,
and the tubes were vortexed. After 30 minutes of incubation in the dark, absorbance was
measured at 750 nm using Agilent Cary Series UV/Vis Spectrophotometer and a calibration
curve was created with the absorbance values and GlyR concentration was calculated.
2.5 CROSSLINKING, STATE DIFFERENTIATION, AND OLIGOMERIC AND
MONOMERIC SEPARATION
2.5.1 I412C-MTS Benzophenone Crosslinking and State Differentiation
MTS-benzophenone, a heterobifunctional crosslinker, was used to develop distance
constraints relative to the position of I412C on GlyR. Allosteric states were also differentiated in
this step. 100 µL of I142C protein sample was added to tubes labeled “resting” and
“desensitized” and 100 µL of IVM sensitive I412C was added to a tube labeled “open.” In the
dark, 1 µL of 5 mM crosslinker was added to the resting and desensitized tubes, and 3 µL added
to the open tube. 5 µL of 200 mM IVM was added to open and 5 µL of 2 M glycine was added to
resting and desensitized. The tubes were shake-incubated in the dark for 1 hour to allow the
crosslinker to bind. The samples were then transferred to quartz cuvettes and exposed to high
intensity UV light with a 420 W hG Arc lamp (260-320 nM) for a total of 20 minutes, flipping
the cuvettes after the first 10 minutes, to activate the crosslinker.
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2.5.2 Oligomeric/Monomeric Separation with SDS-PAGE
20 µL of each sample/state were loaded into a SDS-PAGE (15% resolving, 5% stacking)
along with molecular weight markers and the gel was run. Gel plugs were cut above and below
the 66 kDa BSA migration line to encompass the the inter- and intramolecular crosslinked
subunits (oligomeric) and the solely intramolecular crosslinked subunits (monomeric),
respectively.
2.5.3 In-Gel Trypsin Digestion
The oligomeric and monomeric gel plugs were washed three times with 500 µL of 100
mM ammonium bicarbonate (ambic, pH 6.8) and 50 % acetonitrile (ACN) in non-stick
centrifuge tubes, with the tubes shake-incubated at 37ºC for 15 minutes for each wash. After the
final wash, 1 mL of 100 mM ambic and 500 µL of 10 mM DTT were added to each tube to
reduce the disulfide bond of the cysteine residue and crosslinker, and these were shake-incubated
for 1 hour at 56ºC. The supernatant was removed and, in the dark, 500 µL of ambic and 15 µL of
200 mM iodoacetamide (IAM) were added. The tubes were shake-incubated for another hour at
37ºC in the dark. The supernatant was removed and the plugs were washed with ambic, and
100% ACN was added to shrink the plugs. After shake-incubating for 15 minutes, the ACN was
removed and this ACN step was repeated one more time. After the final removal of ACN, the
samples were dried in a vacufuge for 20 minutes. Enough ambic to cover the plugs was added,
along with 30 µL of 1 mg/mL trypsin, and the samples were shake-incubated at 37ºC for 1 hour
before another 10 µL of trypsin was added and they were shake-incubated overnight at 37ºC. The
supernatant was collected and placed in the fridge and an elution buffer consisting of 0.1%
formic acid (FA), ACN, and 50% dI water was added to the plugs and the samples were shakeincubated for 30 minutes to elute the peptides. The supernatant was added to the tubes in the
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fridge, and elution buffer was added to the plugs, incubated, and supernatant collected again.
The plugs were discarded and the supernatant/elution buffer samples were dried in a vacufuge.
Approximately 50 µL of elution buffer was added to the remaining residue to reconstitute the
pellets, and the tubes were shake-incubated for 2 hours, vortexed for 1 minute, and centrifuged
for 1 minute. Approximately 50 µL of each of these samples were filtered into MS vials.
2.6 MASS FINGERPRINTING OF CROSSLINKED MTS-BENZOPHENONE TO GlyR
PEPTIDES
MS and MS/MS was performed (Table 5) using an Agilent 6530 nano electrospray
ionization time-of-flight mass spectrometer (ESI-qTOF-MS) with an Agilent high performance
liquid chromatography (HPLC) Chip II G4240-62006 ProtID-Chip-150 interface with a 40 nL
enrichment column and 750 µm x 150 mm separation column packed with Zorbac 300SB-C18 5
µM material26. The MS was ran in positive ion mode against internal standards for calibration26.
The data was processed using Agilent Mass Hunter Quantitative Analysis (Version B.06.00)
software with a 10 ppm mass accuracy window26. Modifications accounted for include alkylation
of cysteine by IAM, acrylamidation of cysteine and lysine, oxidation of histidine, methionine,
and tryptophan, and sodiated and potassiated forms of the crosslinker 26. Peptides shifted by the
mass of the crosslinker were identified and run through MS/MS by targeting specific m/z ratios
to refine the crosslinker to precise residues in the peptides. This data was processed using
Agilent Mass Hunter Quantitative Analysis software with a 0.1 Da accuracy window.
Additionally, Protein Prospector (University of California, San Francisco) was used to create
theoretical lists, which were compared with the MS/MS data using Python 1.85 data comparison
software to identify fragments containing the crosslinker 26. See figure 8 for an example spectra
illustrating this method.
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Figure 8. Representative MS spectra, MS/MS spectra, and fragmentation pattern for peptide
VNIFLRQQWNDPR of mutation K116C. The particular m/z ratio corresponding to a
particular RT is found, and ions within this RT correspond to certain fragments. These
masses are compared with theoretical masses obtained from Protein Prospector and matched
to identify ions and fragments. Analysis of the b, y, and a fragmentation ion patterns (labeled
1-5 on MS/MS spectra) indicate that position 116 crosslinks at the di-glutamine region
written in blue.
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Table 5. MS and MS/MS Parameters
Injection Volume
Run Time
Flow
Solvents
Method

Targeted MS/MS

2 µL
11 minutes
Gradient
A: 95% water, 5% ACN, 0.1% FA
B: 95% ACN, 5% water, 0.1% FA
0 minutes – 95% A, 5% B
7 minutes – 40% A, 60% B
9 minutes – 10% A, 90% B
9.1 minutes – 95% A, 5% B
Collision induced dissociation (CID)

CHAPTER 3. RESULTS AND DISCUSSION
The objective of this study was to refine the structure of GlyR through learning more
about the local environment of mutation I412C in the TM4/C-terminal tail region of GlyR in
open, resting, and desensitized states. To accomplish this, a cysteine mutation was inserted in
place of the isoleucine at position 412 in a Cys null background (C41S/C290A/C345S) with the
QuikChange Site-Directed Mutagenesis kit. When the DNA of the desired mutation was
obtained, it was transposed into a bacmid, and the recombinant bacmid DNA was extracted,
which was then used to transfect Sf9 cells, resulting in viral particles to infect and overexpress
the mutated GlyR. Affinity chromatography with 2-aminostrychnine was completed to purify the
mutated GlyR after the membranes were solubilized. Dialysis was performed to reconstitute the
purified GlyR into lipid vesicles in order for it to behave normally. A Western Blot was done to
verify that GlyR was purified and confirm the loss of any protein during the purification steps. A
Modified Lowry Assay was done to determine the concentration of GlyR. To study the three
states separately, no ligand was added to the Cys null GlyR background for the resting state,
excess glycine was added to the Cys null GlyR background for the desensitized state, and IVM
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was added to an IVM-sensitive Cys-null GlyR background with two additional mutations
(F207G/A288G) for the open state. Non-selective, heterobifunctional crosslinker MTSbenzophenone was added to the samples of the three distinguished states and activated with UV
light. The oligomeric and monomeric GlyR were separated with SDS-PAGE; oligomeric GlyR
was associated with inter- and intramolecular crosslinking and a higher molecular weight (MW),
whereas monomeric GlyR was associated with only intramolecular crosslinking and a lower
MW. If a peptide fragment was identified in both monomeric and oligomeric GlyR, it was
classified as intramolecular. GlyR was fragmented with an in-gel trypsin digestion, and a
reducing agent and alkylating agent were added to break the disulfide bond between the inserted
cysteine at position 412 and the crosslinker and to prevent this bond from re-forming,
respectively. Crosslinked peptides were identified from the fragmented GlyR through MS, and
MS/MS will be performed to refine these results.

3.1 RESTING STATE
A Cys null GlyR background with no ligand added during crosslinking was used to study
the resting state. Table 6 contains the peptides found to be crosslinked with MTS-benzophenone
in the resting state (Figure 9).

Table 6. Crosslinked Peptides Found in the Resting State
Intramolecular Crosslinks
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Intermolecular Crosslinks
1

Location
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Charge
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3

8.34
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2
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3
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Modifications
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Figure 9. Crosslinked peptides in resting state. Crystal model of GlyR (PDB 3JAD)
demonstrating crosslinked peptides in the resting state. Red sections are representative
of the crosslinked peptides in Table 6. Mutation I412C is represented as a yellow
sphere. TM3-TM4 crosslinks are not visible in the model.
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3.2 OPEN STATE
An IVM-sensitive, Cys null GlyR background with additional mutations F207G/A288G
and added IVM was used to study the open state. Table 7 contains the peptides found to be
crosslinked with MTS-benzophenone in the open state (Figure 10).
Table 7. Crosslinked Peptides Found in the Open State
Intramolecular Crosslinks
60
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3
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Figure 10. Crosslinked peptides in open state. Crystal model of GlyR (PDB 3JAD)
demonstrating crosslinked peptides in the open state. Red sections are representative of
the crosslinked peptides in Table 7. Mutation I412C is represented as a yellow sphere.
TM3-TM4 crosslinks are not visible in the model.

3.3 DESENSITIZED STATE
A Cys null GlyR background with excess glycine added was used to study the
desensitized state. Table 8 contains the peptides found to be crosslinked with MTSbenzophenone in the open state (Figure 11).
Table 8. Crosslinked Peptides Found in the Desensitized State
Intramolecular Crosslinks
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Intermolecular Crosslinks
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Figure 11. Crosslinked peptides in desensitized state. Crystal model of GlyR (PDB
3JAD) demonstrating crosslinked peptides in the desensititzed state. Red sections are
representative of the crosslinked peptides in Table 8. Mutation I412C is represented as
a yellow sphere. TM3-TM4 crosslinks are not visible in the model.
3.4 DISCUSSION
The mutation I412C has been studied in three allosteric states: resting, open, and
desensitized. MS has been ran for all three states, but MS/MS studies have not been completed
for any of the three states. MS revealed 12 peptides, ranging from 4 to 16 amino acids and a
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maximum charge state of 3, crosslinked to position 412 in the resting state, the majority of which
are in the ECD and the TM3-TM4 loop. This region is not visible in any current crystal models
due to this region’s lack of conservation and lack of a template, stressing the importance of
studying and resolving this region. 10 crosslinked peptides were identified in the open state,
ranging from 7 to 20 amino acids with a maximum charge state of 3. Again, many were in the
ECD and TM3-TM4 loop, but the TM2-TM3 loop was uniquely identified in this state. 9
crosslinked peptides were identified in the desensitized state, ranging from 4 to 17 amino acids
and a maximum charge state of 3. The C-terminal tail was uniquely identified in this state. The
majority of the peptides in this state were also much shorter than those found in the other
allosteric states.
Although only MS has been completed and data analysis is still in progress, there are still
some telling differences between the three allosteric states. Initial MS results show a different
crosslinking pattern between the three states, mapping dynamic changes in receptor structure
upon channel gating and desensitization. The TM3-TM4 loop is identified as a heavily
crosslinked region in every state. This suggests I412C interacts with this loop in all three states,
which makes sense considering position 412 is at the beginning of the C-terminal tail, near TM4,
and thus near the large TM3-TM4 loop. Without refining these results to specific residues with
MS/MS, not much more can be determined regarding these crosslinks. Other regions identified
with crosslinking differ slightly between the states, lending slightly more insightful data; in the
open state, position 412 was found to have crosslinked in the TM2-TM3 loop, and in the
desensitized state, it was found to have crosslinked in the C-terminal tail region. This may
indicate TM2 and TM3 interactions/loop play a role in opening and closing the channel pore,
which is supported by prior studies. The C-terminal tail crosslink may indicate it is crosslinking
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intramolecularly with another subunit. Similar crosslinking patterns are seen in the extracellular
Cys loop in the open and resting states when ligand is bound. However, the crystal model being
used has inherent flaws and is missing details of dynamic regions, and it is bound to an
antagonist, so it may not be an accurate portrayal of the three states. Thus, some of the distances
that appear too far compared to the crosslink length may be due the crystal structure model not
representing the dynamic changes or native states of GlyR well.
CHAPTER 4: CONCLUSION AND FUTURE DIRECTION
4.1 CONCLUSION
This research project aimed to refine the glycine receptor, as current crystal model
structures are poorly resolved in certain areas, such as the C-terminal tail and TM3-TM4
intracellular loop, and the dynamic changes are poorly mapped. This was done using
crosslinking mass spectrometry, which is useful in studying conformational changes in proteins
and protein-protein interactions. CXMS has several advantages over other methods of resolving
protein structure, such as the high sensitivity of MS and the crosslinking reactions being done at
physiological pH so proteins can be studied in their native conformation. Combining the results
from these studies with results from other methods such as X-ray crystallography can lend
useful, unique insight into the structure and dynamics of the glycine receptor.
CXMS was done on all three allosteric states of I412C GlyR, but full data analysis and
MS/MS have not yet been completed. The TM3-TM4 intracellular loop was crosslinked in all
three states, indicating that the C-terminal tail interacts with this region in all three states. The
open state had crosslinks in the TM2-TM3 loop, supporting previous evidence that these play a
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role in the closing/opening of the channel pore. Using Pymol software to measure the distance of
these crosslinked peptides and I412C will offer more information to map these regions.
This research may provide a basis to refine current GlyR models, leading to the
development of novel therapeutics that can effectively target GlyR, treating hyperekplexia and
chronic pain, among other things.
4.2 FUTURE DIRECTION
In the future, it will be important to perform MS/MS on all states of I412C GlyR. Data
analysis of MS/MS studies can lead to the refinement of the precise residue that is crosslinked in
a peptide, rather than the whole peptide, permitting more accurate measurements to map the
receptor and test the accuracy of current models. Additionally, this was only the first of the
needed minimum of three separate trials to validate the crosslinks identified. Other mutations
have and will be studied as well; creating a network of crosslinking information gathered from
mutations in different locations will be helpful in resolving poorly defined areas of current
models, such as the C-terminal tail and the TM3-TM4 intracellular loop, and exposing new
structural information. This study is ongoing, and data will continue to be collected and analyzed
to further refine the dynamic structure of the glycine receptor.
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